奥浦迈(688293) - 2024 Q4 - 年度业绩

Financial Performance - The total operating revenue for 2024 reached ¥297.24 million, representing a 22.26% increase compared to ¥243.12 million in the previous year[4] - The net profit attributable to the parent company was ¥21.13 million, a decrease of 60.90% from ¥54.04 million in the same period last year[4] - The net profit attributable to the parent company after deducting non-recurring gains and losses was ¥6.66 million, down 80.82% from ¥34.72 million year-on-year[4] Assets and Equity - The company's total assets at the end of the reporting period were ¥2,286.33 million, a decrease of 0.68% from the beginning of the period[5] - The equity attributable to the parent company decreased by 2.86% to ¥2,096.82 million compared to the beginning of the period[5] Revenue Growth - The overseas revenue grew by 163.10% year-on-year, indicating successful international strategic deployment[8] Cost and Profitability Challenges - The company faced a significant increase in fixed costs due to the operation of the "Aopu Mai CDMO Biopharmaceutical Commercialization Production Platform," impacting profitability[11] - The corporate income tax rate increased from 15% to 25% due to the loss of high-tech enterprise status, resulting in an additional tax expense of ¥655.96 million[12] Development and Competitiveness - The company has a total of 247 confirmed drug development pipelines using its cell culture products, an increase of 77 from the end of 2023, enhancing market competitiveness[7] - The company is actively preparing to reapply for high-tech enterprise status to regain tax benefits[13]